{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:09:44Z","timestamp":1792501784573,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C1091808"],"award-info":[{"award-number":["NRF-2022R1A2C1091808"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Long noncoding RNA growth arrest-specific transcript 5 (GAS5) has been identified as a tumor suppressor due to its downregulation in several cancers. However, our comprehensive analyses revealed aberrant overexpression of GAS5 in various cancers, with a direct association with SMARCA4 in hepatocellular carcinoma (HCC). Differential expression analyses were conducted using publicly available transcriptome datasets. Functional studies of GAS5 and its downstream targets in HCC were performed via small interfering RNA-mediated knockdown in various HCC cell lines, in vivo xenograft mouse models and spontaneous liver cancer models in\n                    <jats:italic>Ras<\/jats:italic>\n                    -transgenic mice. Here we discover that METTL3-mediated\n                    <jats:italic>N<\/jats:italic>\n                    <jats:sup>6<\/jats:sup>\n                    -methyladenosine modification promoted IGF2BP2 binding, stabilizing GAS5 in HCC. GAS5 expression was significantly upregulated in large cohort of patients with solid cancer, including HCC. Targeted disruption of GAS5 resulted in notable inhibition of growth and proliferation in HCC cells. Further analyses demonstrated that GAS5 enhanced in vitro tumorigenesis and metastatic potential of HCC cells. MicroRNA target prediction and functional validation indicated that GAS5 shared a miR-423-3p binding element with SMARCA4 messenger RNA, functioning as a competing endogenous RNA. This interaction was validated in vitro tumorigenesis assays and in vivo models. Moreover, a synergistic effect was observed with vehicle containing a small interfering RNA mixture targeting both GAS5 and SMARCA4 in these animal models.\n                    <jats:italic>N<\/jats:italic>\n                    <jats:sup>6<\/jats:sup>\n                    -methyladenosine-mediated IGF2BP2 binding stabilizes GAS5, which functions as a competing endogenous RNA for miR-423-3p, thereby enhancing the translation of SMARCA4 messenger RNA. GAS5 acts as a crucial regulator of the oncogenic SMARCA4 in hepatocellular carcinogenesis, presenting a potential therapeutic target for the treatment of liver malignancies.\n                  <\/jats:p>","DOI":"10.1038\/s12276-025-01459-4","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T20:02:45Z","timestamp":1748808165000},"page":"1164-1176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oncogenic function of growth arrest-specific transcript 5 by competing with miR-423-3p to regulate SMARCA4 in hepatocellular carcinoma"],"prefix":"10.1038","volume":"57","author":[{"given":"Sang Yean","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woong","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jeong","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-2965","authenticated-orcid":false,"given":"Jung Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-0584","authenticated-orcid":false,"given":"Won Sang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Woo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"1459_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"1459_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1535-6108(04)00058-3","volume":"5","author":"J Bruix","year":"2004","unstructured":"Bruix, J., Boix, L., Sala, M. & Llovet, J. M. Focus on hepatocellular carcinoma. Cancer Cell 5, 215\u2013219 (2004).","journal-title":"Cancer Cell"},{"key":"1459_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med"},{"key":"1459_CR4","volume":"1","author":"C Gu","year":"2020","unstructured":"Gu, C. et al. RNA m6A modification in cancers: molecular mechanisms and potential clinical applications. Innovation 1, 100066 (2020).","journal-title":"Innovation"},{"key":"1459_CR5","doi-asserted-by":"publisher","first-page":"D303","DOI":"10.1093\/nar\/gkx1030","volume":"46","author":"P Boccaletto","year":"2018","unstructured":"Boccaletto, P. et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 46, D303\u2013D307 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1459_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41580-023-00622-x","volume":"24","author":"H Sun","year":"2023","unstructured":"Sun, H., Li, K., Liu, C. & Yi, C. Regulation and functions of non-m6A mRNA modifications. Nat. Rev. Mol. Cell Biol. 24, 714\u2013731 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1459_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. The role of m6A modification in the biological functions and diseases. Signal Transduct. Target Ther 6, 74 (2021).","journal-title":"Signal Transduct. Target Ther"},{"key":"1459_CR8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen, M. et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 67, 2254\u20132270 (2018).","journal-title":"Hepatology"},{"key":"1459_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang, H. et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 20, 285\u2013295 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1459_CR10","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.3390\/ijms21207633","volume":"21","author":"GI Lambrou","year":"2020","unstructured":"Lambrou, G. I., Hatziagapiou, K. & Zaravinos, A. The non-coding RNA GAS5 and its role in tumor therapy-induced resistance. Int. J. Mol. Sci. 21, 7633 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1459_CR11","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3892\/ol.2020.11809","volume":"20","author":"X Yang","year":"2020","unstructured":"Yang, X., Xie, Z., Lei, X. & Gan, R. Long non-coding RNA GAS5 in human cancer. Oncol. Lett. 20, 2587\u20132594 (2020).","journal-title":"Oncol. Lett."},{"key":"1459_CR12","first-page":"39","volume":"8","author":"J Kaur","year":"2022","unstructured":"Kaur, J. et al. Tumor suppressive effects of GAS5 in cancer cells. Noncoding RNA 8, 39 (2022).","journal-title":"Noncoding RNA"},{"key":"1459_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.21037\/tcr-20-2221","volume":"10","author":"J Li","year":"2021","unstructured":"Li, J., Li, Y., He, X. & Zhao, Q. Gain of GAS5 reveals worse prognosis in kidney renal clear cell carcinoma and liver hepatocellular carcinoma from the Cancer Genome Atlas dataset. Transl. Cancer Res. 10, 223\u2013232 (2021).","journal-title":"Transl. Cancer Res"},{"key":"1459_CR14","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/carcin\/bgv099","volume":"36","author":"R Tao","year":"2015","unstructured":"Tao, R. et al. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis 36, 1136\u20131143 (2015).","journal-title":"Carcinogenesis"},{"key":"1459_CR15","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.4251\/wjgo.v16.i4.1514","volume":"16","author":"Y Pan","year":"2024","unstructured":"Pan, Y. et al. Construction of CDKN2A-related competitive endogenous RNA network and identification of GAS5 as a prognostic indicator for hepatocellular carcinoma. World J. Gastrointest. Oncol. 16, 1514\u20131531 (2024).","journal-title":"World J. Gastrointest. Oncol."},{"key":"1459_CR16","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/CMAR.S297868","volume":"13","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. Long noncoding RNA GAS5 accelerates cholangiocarcinoma progression by regulating hsa-miR-1297. Cancer Manag. Res. 13, 2745\u20132753 (2021).","journal-title":"Cancer Manag. Res."},{"key":"1459_CR17","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1038\/s41388-021-01875-6","volume":"40","author":"SY Kim","year":"2021","unstructured":"Kim, S. Y. et al. SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer. Oncogene 40, 4652\u20134662 (2021).","journal-title":"Oncogene"},{"key":"1459_CR18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jhep.2005.04.012","volume":"43","author":"AG Wang","year":"2005","unstructured":"Wang, A. G. et al. Gender-dependent hepatic alterations in H-ras12V transgenic mice. J. Hepatol. 43, 836\u2013844 (2005).","journal-title":"J. Hepatol."},{"key":"1459_CR19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/hep.30657","volume":"70","author":"HD Yang","year":"2019","unstructured":"Yang, H. D. et al. HDAC6 suppresses Let-7i-5p to elicit TSP1\/CD47-mediated anti-tumorigenesis and phagocytosis of hepatocellular carcinoma. Hepatology 70, 1262\u20131279 (2019).","journal-title":"Hepatology"},{"key":"1459_CR20","doi-asserted-by":"publisher","first-page":"8089","DOI":"10.18632\/oncotarget.3512","volume":"6","author":"HS Kim","year":"2015","unstructured":"Kim, H. S. et al. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget 6, 8089\u20138102 (2015).","journal-title":"Oncotarget"},{"key":"1459_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4161\/trns.2.3.16298","volume":"2","author":"S Marquardt","year":"2011","unstructured":"Marquardt, S., Hazelbaker, D. Z. & Buratowski, S. Distinct RNA degradation pathways and 3\u2032 extensions of yeast non-coding RNA species. Transcription 2, 145\u2013154 (2011).","journal-title":"Transcription"},{"key":"1459_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.molcel.2011.08.027","volume":"44","author":"C Chu","year":"2011","unstructured":"Chu, C., Qu, K., Zhong, F. L., Artandi, S. E. & Chang, H. Y. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol. Cell 44, 667\u2013678 (2011).","journal-title":"Mol. Cell"},{"key":"1459_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He, L. et al. Functions of N6-methyladenosine and its role in cancer. Mol. Cancer 18, 176 (2019).","journal-title":"Mol. Cancer"},{"key":"1459_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0627-5","volume":"9","author":"M Li","year":"2018","unstructured":"Li, M. et al. The long noncoding RNA GAS5 negatively regulates the adipogenic differentiation of MSCs by modulating the miR-18a\/CTGF axis as a ceRNA. Cell Death Dis. 9, 554 (2018).","journal-title":"Cell Death Dis."},{"key":"1459_CR25","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1158\/1078-0432.CCR-17-2376","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Long noncoding RNA LINC01234 functions as a competing endogenous RNA to regulate CBFB expression by sponging miR-204-5p in gastric cancer. Clin. Cancer Res 24, 2002\u20132014 (2018).","journal-title":"Clin. Cancer Res"},{"key":"1459_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.canlet.2021.04.002","volume":"509","author":"J Venkatesh","year":"2021","unstructured":"Venkatesh, J., Wasson, M. D., Brown, J. M., Fernando, W. & Marcato, P. LncRNA\u2013miRNA axes in breast cancer: novel points of interaction for strategic attack. Cancer Lett. 509, 81\u201388 (2021).","journal-title":"Cancer Lett."},{"key":"1459_CR27","doi-asserted-by":"publisher","first-page":"846497","DOI":"10.3389\/fonc.2022.846497","volume":"12","author":"G Lin","year":"2022","unstructured":"Lin, G., Wu, T., Gao, X., He, Z. & Nong, W. Research progress of long non-coding RNA GAS5 in malignant tumors. Front Oncol. 12, 846497 (2022).","journal-title":"Front Oncol."},{"key":"1459_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s12276-023-00944-y","volume":"55","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications. Exp. Mol. Med 55, 487\u2013501 (2023).","journal-title":"Exp. Mol. Med"},{"key":"1459_CR29","doi-asserted-by":"publisher","first-page":"9036","DOI":"10.1002\/cam4.3557","volume":"9","author":"R Ke","year":"2020","unstructured":"Ke, R., Lv, L., Zhang, S., Zhang, F. & Jiang, Y. Functional mechanism and clinical implications of microRNA-423 in human cancers. Cancer Med 9, 9036\u20139051 (2020).","journal-title":"Cancer Med"},{"key":"1459_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal, P. & Roberts, C. W. M. The SWI\/SNF complex in cancer\u2014biology, biomarkers and therapy. Nat. Rev. Clin. Oncol. 17, 435\u2013448 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1459_CR31","doi-asserted-by":"publisher","first-page":"e12791","DOI":"10.1111\/cpr.12791","volume":"53","author":"B Hu","year":"2020","unstructured":"Hu, B., Lin, J. Z., Yang, X. B. & Sang, X. T. The roles of mutated SWI\/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: a review. Cell Prolif. 53, e12791 (2020).","journal-title":"Cell Prolif."},{"key":"1459_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1459_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer, A. D. & Dowdy, S. F. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 28, 109\u2013118 (2018).","journal-title":"Nucleic Acid Ther."},{"key":"1459_CR34","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","volume":"28","author":"AJ Debacker","year":"2020","unstructured":"Debacker, A. J., Voutila, J., Catley, M., Blakey, D. & Habib, N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol. Ther. 28, 1759\u20131771 (2020).","journal-title":"Mol. Ther."},{"key":"1459_CR35","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1002\/adhm.201600416","volume":"5","author":"HJ Park","year":"2016","unstructured":"Park, H. J. et al. Galactosylated lipidoid nanoparticles for delivery of small interfering RNA to inhibit hepatitis C viral replication in vivo. Adv. Health. Mater. 5, 2931\u20132941 (2016).","journal-title":"Adv. Health. Mater."},{"key":"1459_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01459-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01459-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01459-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:18:54Z","timestamp":1751519934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01459-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01459-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5274222\/v1","asserted-by":"object"}]},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.W.N. is the chief executive officer of NEORNAT, Inc. S.Y.K. and M.J.N. are employee of NEORNAT, Inc. The other authors declare no conflict of interest relating to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}